Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw A review

被引:84
作者
Almazrooa, Soulafa A. [1 ]
Woo, Sook-Bin [1 ,2 ]
机构
[1] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Div Oral Med & Dent,Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02115 USA
关键词
Osteonecrosis of the jaw; bisphosphonates; antiangiogenic drugs; radiation; infection; trauma; HERPES-ZOSTER INFECTION; SPONTANEOUS TOOTH EXFOLIATION; HYPERBARIC-OXYGEN THERAPY; SUPPRESSED BONE TURNOVER; NOMA CANCRUM-ORIS; RISK-FACTORS; ORAL BISPHOSPHONATES; ARSENIC TRIOXIDE; CANCER-PATIENTS; ALVEOLAR BONE;
D O I
10.14219/jada.archive.2009.0280
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background. The term "osteonecrosis of the jaw" (ONJ) is used almost synonymously with the term "bisphosphonate-associated ONJ." However, necrosis of the jawbones leading to exposure of bone is associated with other factors. Types of Studies Reviewed. The authors conducted a literature search using PubMed to identify original research articles and case reports that described oral conditions and associated factors that result in sequestrum formation and bone exposure. Results. After reviewing conditions that may led to necrosis of the jawbones, the authors divided the causes of ONJ into the following conditions: systemic medication use; radiation; bacterial, viral and deep fungal infections; direct chemical toxicity; trauma; idiopathy; and other etiologies. Clinical Implications. Clinicians should take a careful history when evaluating patients with ONJ because ONJ may result from one or more factors.
引用
收藏
页码:864 / 875
页数:12
相关论文
共 159 条
[2]   Noma (cancrum oris) associated with oral myiasis in an adult [J].
Aguiar, AMM ;
Enwonwu, CO ;
Pires, FR .
ORAL DISEASES, 2003, 9 (03) :158-159
[3]  
ALMAZROOA SA, 2009, ANN M AM AC OR MED M
[4]  
*AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144
[5]   Hyperbaric oxygen therapy for radionecrosis of the jaw:: A randomized, placebo-controlled, double-blind trial from the ORN96 Study Group [J].
Annane, D ;
Depondt, J ;
Aubert, P ;
Villart, M ;
Géhanno, P ;
Gajdos, P ;
Chevret, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4893-4900
[6]  
Ashamalla HL, 1996, CANCER, V77, P2407, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2407::AID-CNCR33>3.3.CO
[7]  
2-X
[8]  
Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
[9]  
Auluck Ajit, 2005, J Can Dent Assoc, V71, P757
[10]   Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates [J].
Bagan, Jose V. ;
Jimenez, Yolanda ;
Gomez, Dolores ;
Sirera, Rafael ;
Poveda, Rafael ;
Scully, Crispian .
ORAL ONCOLOGY, 2008, 44 (11) :1088-1089